JCI - The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo

The IL-6R α chain controls lung CD4⁺CD25⁺ Treg development and function during allergic airway inflammation in vivo

Aysefa Doganci, Tatjana Eigenbrod, Norbert Krug, George T. De Sanctis, Michael Hausding, Veit J. Erpenbeck, El-Bdaoui Haddad, Edgar Schmitt, Tobias Bopp, Karl-J. Kallen, Udo Herz, Steffen Schmitt, Cornelia Luft, Olaf Hecht, Jens M. Hohlfeld, Hiroaki Ito, Norihiro Nishimoto, Kazuyuki Yoshizaki, Tadamitsu Kishimoto, Stefan Rose-John, Harald Renz, Markus F. Neurath, Peter R. Galle, Susetta Finotto

Published in Volume 115, Issue 2

J Clin Invest. 2005; 115(2):313–325 doi:10.1172/JCI22433

Abstract | Full text | PDF

Options: View larger image (or click on image)

Figure 3

Antiinflammatory mechanism of local treatment with anti–IL-6R antibodies. Blockade of IL-6R led to a downregulation of IL-4 (P = 0.05) (A), and, at higher doses (100 μg/day), of IL-5 (P = 0.029) (B) in the lungs of treated mice. These findings were accompanied by downregulation of the total number of eosinophils (P = 0.0002) in BALF (C) and CD4⁺ cells (P = 0.05) in the airways of treated mice (D and E). (D) CD4⁺ lung cells were stained by using monoclonal anti-CD4 antibodies (BD), and immunohistochemistry was performed as previously described (34). Pictures were taken with an Olympus inverted microscope connected to a digital camera. Original magnification, ×400. (E) The number of CD4⁺ lung cells obtained from 1 lung after CD4 isolation is reported for different groups. *P < 0.05; ***P < 0.001.